Treatment of prostate cancer cells with mithramycin A (MitA), a natural SP1 inhibitor, led to the inhibition of EMT invasive markers and Wnt/β-cadherin signaling, alternating the metastatic ability of cells [53]. Here, SP1 is linked to prostate carcinoma.